In summary now that PBR is bleeding money things are changing as far as getting rid of the dead weight and it is still a work in progress.

FORBES: Can Petrobras Possibly Disappoint More?

Both Novartis and Merck (nyse: MRK - news - people ) are nearing FDA approval for once-a-day pills that work in a fashion similar to Byetta, although without the promise of weight loss.

FORBES: Fat City